Diseases / Osteosarcoma
Osteosarcoma
DiseaseOsteosarcoma is a primary malignant bone tumor characterized by production of immature bone (osteoid) by malignant cells, most often arising in long bones of adolescents and young adults.
- Trials
- 466
- Recruiting
- 85
- Completed
- 205
- With results
- 85
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 3 | — | — | — | 1 | 1 | — | — | 4 | — | — | — | 9 |
| Phase 1 | 20 | 1 | — | 9 | 49 | 10 | 7 | 2 | 4 | — | — | — | 102 |
| Phase 1/2 | 15 | 2 | — | 3 | 16 | 5 | — | — | 4 | — | — | — | 45 |
| Phase 2 | 21 | 6 | — | 19 | 74 | 16 | 3 | 1 | 18 | — | — | — | 158 |
| Phase 2/3 | — | — | — | — | 1 | — | — | 1 | 3 | — | — | — | 5 |
| Phase 3 | 2 | — | — | 2 | 7 | 2 | — | — | — | — | — | — | 13 |
| Phase 4 | — | — | — | — | 1 | — | — | — | 1 | — | — | — | 2 |
| Not applicable | 6 | 2 | — | 3 | 12 | 2 | 4 | — | 8 | — | — | — | 37 |
| Unknown | 18 | 3 | 1 | 2 | 44 | 5 | 1 | — | 17 | 1 | 2 | 1 | 95 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Osteosarcoma | 9 | 102 | 45 | 158 | 5 | 13 | 2 | 37 | 95 | 466 |
| Sarcoma | 6 | 52 | 16 | 69 | 2 | 5 | 1 | 16 | 26 | 193 |
| Neuroblastoma | 1 | 51 | 15 | 35 | — | 3 | — | 5 | 6 | 116 |
| Sarcoma, Ewing | 1 | 27 | 17 | 32 | 1 | 2 | 1 | 14 | 19 | 114 |
| Rhabdomyosarcoma | 1 | 27 | 14 | 38 | — | — | 1 | 6 | 6 | 93 |
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 20 | 5 | 35 | — | 2 | — | 5 | 2 | 70 |
| Wilms Tumor | — | 25 | 5 | 23 | — | 2 | — | 3 | 1 | 59 |
| Medulloblastoma | — | 16 | 3 | 22 | — | 4 | — | 3 | 1 | 49 |
| Chondrosarcoma | 2 | 6 | 4 | 15 | — | 2 | — | 8 | 6 | 43 |
| Bone Neoplasms | 2 | 7 | 3 | 12 | 1 | 1 | — | 4 | 12 | 42 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 54 | 2 |
| 2 | Children's Oncology Group | 28 | 3 |
| 3 | Peking University People's Hospital | 26 | 0 |
| 4 | Memorial Sloan Kettering Cancer Center | 21 | 0 |
| 5 | St. Jude Children's Research Hospital | 19 | 0 |
| 6 | M.D. Anderson Cancer Center | 12 | 0 |
| 7 | Emory University | 8 | 0 |
| 8 | Istituto Ortopedico Rizzoli | 7 | 0 |
| 9 | Italian Sarcoma Group | 7 | 0 |
| 10 | Second Affiliated Hospital, Zhejiang University, School of Medicine | 6 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Ifosfamide | 30 |
| 2 | Methotrexate | 29 |
| 3 | Doxorubicin | 26 |
| 4 | Cyclophosphamide | 24 |
| 5 | Cisplatin | 22 |
| 6 | Filgrastim | 18 |
| 7 | Etoposide | 17 |
| 8 | Gemcitabine | 16 |
| 9 | Leucovorin | 14 |
| 10 | Magnetic Resonance Spectroscopy | 12 |
Evidence
- Results reported
- 41.5%85 of 205 completed
- Published
- 21%43 of 205 completed
- Primary endpoint met
- 25%1 of 4 analyses
- Median months to report
- 13
Documents disclosed
Trial profile
- Median enrollment
- 43
- Median duration
- 57months
- Countries
- 39
- Study sites
- 1831
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 19
- Phase 1
- 24
- Phase 1/2
- 42
- Phase 2
- 43
- Phase 2/3
- 50
- Phase 3
- 130
- Phase 4
- 210
- Not applicable
- 60
- Unknown
- 100
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 82 |
| 2 | Houston | United States | 80 |
| 3 | Los Angeles | United States | 64 |
| 4 | Boston | United States | 58 |
| 5 | Philadelphia | United States | 54 |
| 6 | Memphis | United States | 52 |
| 7 | Cincinnati | United States | 51 |
| 8 | Atlanta | United States | 50 |
| 9 | Chicago | United States | 50 |
| 10 | Seattle | United States | 50 |
Terminations
- Terminated
- 41
- Withdrawn
- 15
- Suspended
- 4
- Stopped for recruitment
- 4.1%19 of 466 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04539366 Suspended | Suspended | Other - review of safety data | 2040-12-31 |
| NCT05116800 Withdrawn | Withdrawn | IND withdrawn | 2030-08-31 |
| NCT05691478 Suspended | Suspended | Other - Extend the observation period for current patients | 2030-03-20 |
| NCT04824352 Suspended | Suspended | Because we then tried another trial with radomised design. | 2026-04-01 |
| NCT06341712 Terminated | Terminated | The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges | 2026-02-27 |
| NCT05958199 Suspended | Suspended | Business decision | 2025-09-20 |
| NCT06438783 Terminated | Terminated | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns. | 2025-06-18 |
| NCT04544995 Terminated | Terminated | Sponsor Decision | 2025-04-23 |
| NCT03612466 Withdrawn | Withdrawn | Study withdrawn before any participants could be enrolled. Issues being able to effectively recruit participants into the study. | 2024-09-30 |
| NCT04751383 Terminated | Terminated | Drug supply issues | 2024-09-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: